Novartis To Cut 8,000 Jobs In Global Restructure
Follows Through On Plan For Leaner Organization
CEO Vas Narasimhan wants the company to be more agile and identify more blockbuster opportunities.
You may also be interested in...
Six months after taking the reins, Thomas Schinecker has unveiled a new approach aimed at preserving Roche’s 'R&D diversity' while cutting costly Phase III failures.
President of Innovative Medicines International and chief commercial officer Marie-France Tschudin will leave Novartis after nearly seven years.
While biotech layoffs and big pharma restructuring dominate the news in 2023, the sector’s job market remains buoyant.